The insulin sensitizing agent, rosiglitazone, is a PPARγ agonist used in the clinic to treat type II diabetes and recently has been reported to affect the phenotypic switch of macrophages from a pro to an anti-inflammatory profile as well as to affect macrophage infiltration into the EF pad [27]. The gene discussed is INS; the disease is type 2 diabetes mellitus.